Literature DB >> 30111571

Infection Dynamics of Hepatitis E Virus in Wild-Type and Immunoglobulin Heavy Chain Knockout JH -/- Gnotobiotic Piglets.

Danielle M Yugo1, C Lynn Heffron1, Junghyun Ryu2, Kyungjun Uh2, Sakthivel Subramaniam1, Shannon R Matzinger1, Christopher Overend1, Dianjun Cao1, Scott P Kenney3, Harini Sooryanarain1, Thomas Cecere1, Tanya LeRoith1, Lijuan Yuan1, Nathaniel Jue4, Sherrie Clark-Deener4, Kiho Lee2, Xiang-Jin Meng5.   

Abstract

Hepatitis E virus (HEV), the causative agent of hepatitis E, is an important but incompletely understood pathogen causing high mortality during pregnancy and leading to chronic hepatitis in immunocompromised individuals. The underlying mechanisms leading to hepatic damage remain unknown; however, the humoral immune response is implicated. In this study, immunoglobulin (Ig) heavy chain JH -/- knockout gnotobiotic pigs were generated using CRISPR/Cas9 technology to deplete the B-lymphocyte population, resulting in an inability to generate a humoral immune response to genotype 3 HEV infection. Compared to wild-type gnotobiotic piglets, the frequencies of B lymphocytes in the Ig heavy chain JH -/- knockouts were significantly lower, despite similar levels of other innate and adaptive T-lymphocyte cell populations. The dynamic of acute HEV infection was subsequently determined in heavy chain JH -/- knockout and wild-type gnotobiotic pigs. The data showed that wild-type piglets had higher viral RNA loads in feces and sera compared to the JH -/- knockout pigs, suggesting that the Ig heavy chain JH -/- knockout in pigs actually decreased the level of HEV replication. Both HEV-infected wild-type and JH -/- knockout gnotobiotic piglets developed more pronounced lymphoplasmacytic hepatitis and hepatocellular necrosis lesions than other studies with conventional pigs. The HEV-infected JH -/- knockout pigs also had significantly enlarged livers both grossly and as a ratio of liver/body weight compared to phosphate-buffered saline-inoculated groups. This novel gnotobiotic pig model will aid in future studies into HEV pathogenicity, an aspect which has thus far been difficult to reproduce in the available animal model systems.IMPORTANCE According to the World Health Organization, approximately 20 million HEV infections occur annually, resulting in 3.3 million cases of hepatitis E and >44,000 deaths. The lack of an efficient animal model that can mimic the full-spectrum of infection outcomes hinders our ability to delineate the mechanism of HEV pathogenesis. Here, we successfully generated immunoglobulin heavy chain JH -/- knockout gnotobiotic pigs using CRISPR/Cas9 technology, established a novel JH -/- knockout and wild-type gnotobiotic pig model for HEV, and systematically determined the dynamic of acute HEV infection in gnotobiotic pigs. It was demonstrated that knockout of the Ig heavy chain in pigs decreased the level of HEV replication. Infected wild-type and JH -/- knockout gnotobiotic piglets developed more pronounced HEV-specific lesions than other studies using conventional pigs, and the infected JH -/- knockout pigs had significantly enlarged livers. The availability of this novel model will facilitate future studies of HEV pathogenicity.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  B cell depletion; HEV; Ig heavy chain knockout; gnotobiotic pig; hepatitis E virus

Mesh:

Substances:

Year:  2018        PMID: 30111571      PMCID: PMC6189505          DOI: 10.1128/JVI.01208-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  A novel virus in swine is closely related to the human hepatitis E virus.

Authors:  X J Meng; R H Purcell; P G Halbur; J R Lehman; D M Webb; T S Tsareva; J S Haynes; B J Thacker; S U Emerson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

Review 2.  Pathogenetic elements of hepatitis E and animal models of HEV infection.

Authors:  Krzysztof Krawczynski; Xiang-Jin Meng; Jolanta Rybczynska
Journal:  Virus Res       Date:  2011-03-23       Impact factor: 3.303

3.  Piglets produced from cloned blastocysts cultured in vitro with GM-CSF.

Authors:  Kiho Lee; Bethany K Redel; Lee Spate; Jennifer Teson; Alana N Brown; Kwang-Wook Park; Eric Walters; Melissa Samuel; Clifton N Murphy; Randall S Prather
Journal:  Mol Reprod Dev       Date:  2013-01-22       Impact factor: 2.609

4.  Systematic pathogenesis and replication of avian hepatitis E virus in specific-pathogen-free adult chickens.

Authors:  P Billam; F F Huang; Z F Sun; F W Pierson; R B Duncan; F Elvinger; D K Guenette; T E Toth; X J Meng
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Virus-specific intestinal IFN-gamma producing T cell responses induced by human rotavirus infection and vaccines are correlated with protection against rotavirus diarrhea in gnotobiotic pigs.

Authors:  Lijuan Yuan; Ke Wen; Marli S P Azevedo; Ana M Gonzalez; Wei Zhang; Linda J Saif
Journal:  Vaccine       Date:  2008-04-18       Impact factor: 3.641

Review 6.  Hepatitis E and pregnancy: understanding the pathogenesis.

Authors:  Udayakumar Navaneethan; Mayar Al Mohajer; Mohamed T Shata
Journal:  Liver Int       Date:  2008-07-25       Impact factor: 5.828

7.  Development and validation of a negative-strand-specific reverse transcription-PCR assay for detection of a chicken strain of hepatitis E virus: identification of nonliver replication sites.

Authors:  P Billam; F W Pierson; W Li; T LeRoith; R B Duncan; X J Meng
Journal:  J Clin Microbiol       Date:  2008-06-18       Impact factor: 5.948

8.  Chronic hepatitis E virus infection in liver transplant recipients.

Authors:  Elizabeth B Haagsma; Arie P van den Berg; Robert J Porte; Cornelis A Benne; Harry Vennema; Johan H J Reimerink; Marion P G Koopmans
Journal:  Liver Transpl       Date:  2008-04       Impact factor: 5.799

Review 9.  Hepatitis E virus.

Authors:  Suzanne U Emerson; Robert H Purcell
Journal:  Rev Med Virol       Date:  2003 May-Jun       Impact factor: 6.989

Review 10.  Hepatitis E virus: animal reservoirs and zoonotic risk.

Authors:  X J Meng
Journal:  Vet Microbiol       Date:  2009-03-20       Impact factor: 3.293

View more
  7 in total

Review 1.  Application of genome-editing systems to enhance available pig resources for agriculture and biomedicine.

Authors:  Kiho Lee; Kayla Farrell; Kyungjun Uh
Journal:  Reprod Fertil Dev       Date:  2019-01       Impact factor: 2.311

2.  TET family regulates the embryonic pluripotency of porcine preimplantation embryos by maintaining the DNA methylation level of NANOG.

Authors:  Kyungjun Uh; Junghyun Ryu; Kayla Farrell; Noah Wax; Kiho Lee
Journal:  Epigenetics       Date:  2020-05-13       Impact factor: 4.528

Review 3.  Swine hepatitis E virus: Cross-species infection, pork safety and chronic infection.

Authors:  Harini Sooryanarain; Xiang-Jin Meng
Journal:  Virus Res       Date:  2020-04-23       Impact factor: 3.303

4.  Frequency of off-targeting in genome edited pigs produced via direct injection of the CRISPR/Cas9 system into developing embryos.

Authors:  Kayla Carey; Junghyun Ryu; Kyungjun Uh; Andrea J Lengi; Sherrie Clark-Deener; Benjamin A Corl; Kiho Lee
Journal:  BMC Biotechnol       Date:  2019-05-06       Impact factor: 2.563

5.  The U-Rich Untranslated Region of the Hepatitis E Virus Induces Differential Type I and Type III Interferon Responses in a Host Cell-Dependent Manner.

Authors:  Harini Sooryanarain; Connie L Heffron; Xiang-Jin Meng
Journal:  mBio       Date:  2020-01-14       Impact factor: 7.867

Review 6.  Improvements in Gene Editing Technology Boost Its Applications in Livestock.

Authors:  Iuri Viotti Perisse; Zhiqiang Fan; Galina N Singina; Kenneth L White; Irina A Polejaeva
Journal:  Front Genet       Date:  2021-01-08       Impact factor: 4.599

Review 7.  Application of Gene Editing Technology in Resistance Breeding of Livestock.

Authors:  Sutian Wang; Zixiao Qu; Qiuyan Huang; Jianfeng Zhang; Sen Lin; Yecheng Yang; Fanming Meng; Jianhao Li; Kunli Zhang
Journal:  Life (Basel)       Date:  2022-07-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.